Saratov JOURNAL of Medical and Scientific Research

Innovative medicines for treatment of psoriatic arthritis

Year: 2015, volume 11 Issue: №3 Pages: 423-425
Heading: Dermatovenerology Article type: Review
Authors: Levitan A.l., Reshetko O.V.
Organization: Saratov State Medical University

The problem of effective treatment of psoriatic arthritis has not been solved yet. The search for new therapeutic options is very active in many directions. At the stage of clinical trials are drugs that block interleukin-17-a (secukinumab, ixekizumab, brodalumab), drugs that suppress interleukin-12 and interleukin-23 (ustekinumab). To modern means to ensure psoriatic arthritis include drugs that are inhibitors of small molecules orkinase pathways (apremilast, tofacitinib).

1. Nasonov EL. Rheumatology: Clinical guidelines. M.: GEO-TAR-Media, 2008; 282 p.
2. Nasonov EL. Rheumatology: Clinical guidelines. M.: GEO-TAR-Media, 2010; 752 p.
3. Federal guidelines for rheumatology.
4. Siba P. Raychaudhuri. Role of IL-17 in Psoriasis and Pso-riatic Arthritis. Clinical Reviews in Allergy & Immunology 2013; 44: 183-193
5. Kirkham BW, Kavanaugh A, Reich K. Interleukin-17A: a unique pathway in immune-mediated diseases: psoriasis, pso-riatic arthritis and rheumatoid arthritis. Immunology 2014; 141: 133-142
6. Mclnnes IB, Sieper J, Braun J, et al. Efficacy and safety of secukinumab, a fully human anti-interleukin-17A monoclonal antibody, in patients with moderate-to-severe psoriatic arthritis: a 24-week, randomised, double-blind, placebo-controlled, phase II proof-of-concept trial. Annals Rheumatic Disease 2014; 73: 349-356
8. Mease PJ, Genovese MC, Greenwald MW, et al. Broda-lumab, an Anti-I LI 7RA Monoclonal Antibody, in Psoriatic Arthritis. The New England Journal of Medicine 2014; 370: 2295-2306
9. Ritchlin C, Haas-Smith SA, Hicks D, et al. Patterns of cy-tokine production in psoriatic synovium. Rheumatology 1998; 25: 1544-1552
10. Gottlieb A, Menter A, Mendelson A, et al. Ustekinum-ab, a human interleukin-12/23 monoclonal antibody, for psoriatic arthritis: randomised, double-blind, placebo-controlled, crossover trial. Lancet 2009; 373: 633-640
11. Schafer P. Apremilast mechanism of action and application to psoriasis and psoriatic arthritis. Biochemical Pharmacology 2012; 83: 1583-1590
12. McCann FE, Palfreeman AC, Andrews M, et al. Apremilast, a novel PDE4 inhibitor, inhibits spontaneous production of tumour necrosis factor-alpha from human rheumatoid synovial cells and ameliorates experimental arthritis. Arthritis Re-saerch&Terapy 2010; 12: R107
13. Kavanaugh A, Mease PJ, Gomez-Reino JJ, et al. Treatment of psoriatic arthritis in a phase 3 randomised, placebo-controlled trial with apremilast,an oral phosphodiesterase 4 inhibitor.Annals Rheumatic Disease 2014; 73: 1020-1026

2015_03-01_423-425.pdf250.65 KB

No votes yet